SB 203580 hydrochloride

• CAT Number: I005227
• CAS Number: 869185-85-3
• Molecular Formula: C21H16FN3OS • HCl
• Molecular Weight: 413.90
• Purity: ≥95%
• Target: p38
• Solubility: ethanol:30 mg/ml;DMSO:30 mg/ml;DMF:30 mg/ml
• Storage: Store at -20C
• IC50: 0.3 -0.5 mM
• IUPAC Name: 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine;hydrochloride
• InChI: InChI=1S/C21H16FN3OS.ClH/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15;/h2-13H,1H3,(H,24,25);1H
• InChIKey: WOSGGXINSLMASH-UHFFFAOYSA-N
• SMILES: CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F.Cl

SB 203580 hydrochloride（Cat No.:I005227）is a potent, selective inhibitor of p38 MAP kinase, specifically targeting the p38α and p38β isoforms. It plays a crucial role in the regulation of cellular responses to stress and inflammation, making it a valuable tool in studying signal transduction pathways. By inhibiting p38 MAPK, SB 203580 hydrochloride is used to explore the mechanisms of inflammatory diseases, cancer, and other conditions related to stress response. Its specificity makes it ideal for biochemical and pharmaceutical research applications, enabling precise analysis of p38-mediated pathways.

Reference

[1]. Lali FV, et al. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem. 2000 Mar 10;275(10):7395-402.
[2]. Birkenkamp KU, et al. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol. 2000 Sep;131(1):99-107.
[3]. Zhang H, et al. Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK. Apoptosis. 2012 Apr;17(4):325-34.
[4]. Barancik M, et al. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol. 2000 Mar;35(3):474-83.
[5]. Jin N, et al. The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus. Int Immunopharmacol. 2011 Sep;11(9):1319-26.